Impact of a Novel Extended Depth of Focus Intraocular Lens on Visual and Lifestyle Enhancement

Sponsor
Alanna Nattis, DO (Other)
Overall Status
Recruiting
CT.gov ID
NCT04570579
Collaborator
(none)
46
Enrollment
1
Location
14.6
Anticipated Duration (Months)
3.2
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

The introduction of presbyopia-correcting intraocular lenses (PC-IOLs) has provided cataract and refractive surgeons the ability to provide patients with a wider range of visual success and spectacle independence post-cataract surgery.Multifocal (MFIOL) IOLs have the ability to provide near and distance vision, and in the case of trifocal IOLs, near, intermediate and distance. Despite the significant technological evolution of MFIOL's, the potential for visual disturbances, such as glare, halos and starbursts still exists-and in much greater frequency compared to their monofocal counterparts.

Extended depth of focus (EDOF) IOLs aim to provide patients with a functional range of vision, with a similar visual disturbance profile to a monofocal lens. In this way, this subset of PC-IOL's can offer patients some degree of spectacle independence, with a significantly lower incidence of visual disturbances.

The Vivity Extended Vision IOL is the first of its kind to offer Wavefront Stretching technology, providing patients with an excellent extended range of vision from intermediate to distance, as well as some functional near vision. Prior studies have demonstrated very good vision in both bright and dim lighting conditions, as well as a high degree of spectacle independence with the Vivity IOL, as compared to a monofocal IOL.

Studies evaluating the ability of the Vivity IOL to provide a significant impact on patient lifestyle (e.g. patient independence from spectacles for most activities with a low rate of visual disturbances) in the United States in a 'real-world' setting have yet to be performed. In addition, influence of pre-and-perioperative variables such as sex, age, prior refractive surgery, IOL formula used, axial length, astigmatism, use of intraoperative aberrometry, femtosecond laser and pupillary expansion devices has yet to be evaluated on the postoperative success of this IOL.

This study will be comprised of patients with visually significant cataracts who will undergo cataract extraction with implantation of the spherical and/or toric models of the Vivity Extended Vision (Alcon, Fort Worth TX) intraocular lens. Upon decision of the patient and surgeon to undergo surgery, patients will be offered the option to enroll in this observational study.

Condition or DiseaseIntervention/TreatmentPhase
  • Device: Vivity Extended Depth of Focus Intraocular Lens

Detailed Description

Presbyopia-correcting intraocular lenses (PC-IOLs) provide cataract and refractive surgeons with an effective treatment option for presbyopia, allowing patients increased spectacle independence post-cataract surgery. Different IOL designs have been developed based on differing optical principals, such as diffractive, refractive and extended depth of focus (EDOF) design. Most commercially available MFIOLs have two optical zones, one that provides distance vision, and the second that provides near vision (i.e. "bifocal IOLs"). Most recently, trifocal IOLs have been released, with the aim of providing a third (intermediate) focal point, and hence an extended range of vision in pseudophakic patients. While being able to provide patients with near, intermediate and distance vision, most MFIOL's carry the risk of increased visual disturbances, such as glare, starbursts, and halos, which for a small percentage of patients may become quite bothersome or even debilitating.

Extended depth of focus (EDOF) IOLs aim to provide an extended range of vision from intermediate to distance, with a similar visual disturbance profile to their monofocal counterparts. Prior to recent FDA approval, there was only one other EDOF IOL on the market in the US, which, although provides an extended visual range, still had a significant incidence of starbursts and visual disturbances in some patients. FDA approved in February 2020, the Vivity Extended Vision Lens has demonstrated the ability to provide patients with an extended range of vision, excellent contrast sensitivity and visual disturbance profile comparable to a monofocal IOL, as well as high rates of spectacle independence for most activities.

The Vivity Extended Vision IOL (Alcon Laboratories, Fort Worth TX) is an EDOF IOL made of hydrophobic acrylic. This non-diffractive lens was designed to mitigate the effect of presbyopia by providing an extended depth of focus through patented Wavefront Shaping technology. In clinical trials, Vivity has demonstrated significantly better intermediate and near vision as compared to a monofocal IOL, as well as superior spectacle independence scores. Additionally, a validated questionnaire regarding visual disturbances showed the Vivity to have comparable rates of starburst, glare and halos to its monofocal counterpart.

In an era where intermediate vision has become very important (e.g. using laptops, tablets, seeing the dashboard in a car), many patients express desire for visual correction at all possible focal points. Vivity appears to deliver this with minimal visual side effects-even less so as compared to other MFIOL's. This is a valuable aspect of Vivity; spectacle independence is an important factor for many patients-however if this is coupled with debilitating glare, haloes or other visual disturbances, dissatisfaction will ultimately result.

Multiple studies have explored variables that may influence postoperative success of these MFIOLs, including the impact of dry eye, prior corneal refractive surgery, and proper preoperative consent/expectations.

A study has yet to be performed evaluating not only preoperative factors, such as astigmatism, and prior corneal refractive surgery, but also perioperative and intraoperative factors that may also play a role in success of the Vivity IOL implant. In this prospective, nonrandomized "real-world" study, the impact of perioperative factors, such as IOL formulae used, use of femtosecond laser, use of intraoperative aberrometry, as well use of pupillary expansion devices on surgical success will be evaluated. Surgical success will be defined as uncorrected distance, intermediate and near visual acuity (UDVA, UIVA and UNVA, respectively) of 20/40 or better (both monocular and binocular) as well as high levels of patient satisfaction, which will be recorded with a Visual Disturbance Questionnaire, Spectacle Independence Questionnaire, and Visual Quality Questionnaire.

Results will provide never-before-published data on important preoperative as well as perioperative factors that may influence success and patient satisfaction with Vivity IOL implantation

Study Design

Study Type:
Observational
Anticipated Enrollment :
46 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Impact of a Novel Extended Depth of Focus Intraocular Lens on Visual and Lifestyle Enhancement
Actual Study Start Date :
Oct 14, 2020
Anticipated Primary Completion Date :
Jan 1, 2022
Anticipated Study Completion Date :
Jan 1, 2022

Arms and Interventions

ArmIntervention/Treatment
Observational cohort

This is a prospective, nonrandomized study of patients undergoing bilateral cataract surgery with implantation of the spherical Vivity and/or Vivity toric IOL. Preoperative patient data such as age, sex, prior ocular history, medical history, and intraocular lens calculations/formulae used will be recorded. Uncorrected and best-corrected visual acuity will be measured at distance (4m), intermediate (60cm) and near (40cm). All 3 surveys will be administered prior to surgery (at baseline) and at 3 months postoperative, regarding spectacle independence, visual disturbances, and visual quality. A proper perioperative record will be maintained, documenting planned IOL implantation, actual IOL implant used, use of femtosecond laser, use of intraoperative aberrometry, and use of pupillary expansion devices. Patients will be examined 1 day ("postoperative day 1)", 1 week ("postoperative week 1"), 1 month ("postoperative month 1") and 3 months ("postoperative month 3") following surgery.

Device: Vivity Extended Depth of Focus Intraocular Lens
Patients selected to have bilateral sequential cataract surgery using the Vivity (spherical and/or toric where applicable) intraocular lens implant will subsequently be offered enrollment into this observational study. Visual outcomes will be recorded at postoperative day 1, week 1, month 1 and month 3.

Outcome Measures

Primary Outcome Measures

  1. Visual success - uncorrected distance visual acuity [Change in visual acuity outcomes will be assessed at baseline and compared to postoperative month 3]

    Change in uncorrected distance visual acuity between baseline and at 3 months postoperative will be assessed.

  2. Visual success- uncorrected intermediate visual acuity [Change in visual acuity outcomes will be assessed at baseline and compared to postoperative month 3]

    Change in uncorrected intermediate visual acuity between baseline and at 3 months postoperative will be assessed.

  3. Visual success- uncorrected near visual acuity [Change in visual acuity outcomes will be assessed at baseline and compared to postoperative month 3]

    Change in uncorrected near visual acuity between baseline and at 3 months postoperative will be assessed.

  4. Visual success - best corrected distance visual acuity [Change in visual acuity outcomes will be assessed at baseline and compared to postoperative month 3]

    Change in best-corrected distance visual acuity between baseline and at 3 months postoperative will be assessed.

  5. Visual success- best-corrected intermediate visual acuity [Change in visual acuity outcomes will be assessed at baseline and compared to postoperative month 3]

    Change in best-corrected intermediate visual acuity between baseline and at 3 months postoperative will be assessed.

  6. Visual success- best-corrected near visual acuity [Change in visual acuity outcomes will be assessed at baseline and compared to postoperative month 3]

    Change in best-corrected near visual acuity between baseline and at 3 months postoperative will be assessed.

  7. Visual quality of life measures - visual disturbances [Questionnaires will be administered at baseline visit (preoperative) and at 3 months postoperative]

    Change in responses in regard to patient lifestyle satisfaction using a Visual Disturbance Questionnaire at baseline and 3 months postoperative will be assessed. This will be assessed on a scale of 0 - 4 in severity (0 = no disturbance, 4 = very bothersome disturbance). Total scores will be tallied and compared between baseline and postoperative month 3 responses.

  8. Visual quality of life measures - Visual quality [Questionnaires will be administered at baseline visit (preoperative) and at 3 months postoperative]

    Change in responses in regard to patient lifestyle satisfaction using a Visual Quality Questionnaire at baseline and 3 months postoperative will be assessed. This will be assessed on a scale of 1 - 5 in severity (1 = no issues with vision interfering with daily activities, 5 = vision interfering with nearly every activity listed). Total scores will be tallied and compared between baseline and postoperative month 3 responses.

  9. Visual quality of life measures - spectacle independence [Questionnaires will be administered at baseline visit (preoperative) and at 3 months postoperative]

    Change in responses in regard to patient lifestyle satisfaction using a Spectacle Independence Questionnaire at baseline and 3 months postoperative will be assessed. This will be assessed on a scale of 0 - 4 in severity (0 = never using spectacles for activities, 4 = always using spectacles for every activity listed). Total scores will be tallied and compared between baseline and postoperative month 3 responses.

Other Outcome Measures

  1. Adverse events [Safety measures and assessment for adverse events will be assessed at all time points (baseline, postoperative day 1, postoperative week 1, postoperative month 1, postoperative month 3)]

    Adverse events (e.g. surgical complications) in relation to Vivity IOL implantation will be evaluated at each time point. Any adverse events will be documented/reported and treated, if necessary

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Visually significant bilateral cataracts, with planned cataract extraction using phacoemulsification and clear corneal incision

  • Ability to comprehend and willing to sign informed consent

  • Ability to complete all required postoperative follow up procedures.

  • 18 years or older

  • male or female

Exclusion Criteria:
  • Patients who lack ability to consent, and who cannot provide clear understanding of the surgical procedure as well as possible adverse side effects (e.g. dysphotopsias) of the IOL will be excluded

  • Patients who are professional night drivers, pilots and those with other occupations for whom induced dysphotopsia could put their career at risk will be excluded

  • Patients who have preexisting significant ocular pathology, including severe dry eye, retina, optic nerve (including moderate-severe glaucoma) and corneal pathologies (e.g. corneal dystrophy, edema, significant scarring), limiting or affecting visual potential, in the opinion of the surgeon, will be excluded

  • Patients whose IOL calculations are outside the range available for the Vivity IOL will be excluded.

  • Patients who have history of past eye trauma with evidence of/suspected zonular laxity, and those with pseudoexfoliation will be excluded.

  • Patients with prior corneal surgery (namely, radial keratotomy (RK), corneal transplantation of any kind) will be excluded from the study (post-myopic and hyperopic LASIK and PRK patients will be permitted to participate in the study).

  • Pregnant and/or lactating patients will be excluded from the study.

  • Patients with perioperative or intraoperative complications that do not allow for implantation of the Vivity IOL will be excluded.

  • Inability to implant the Vivity IOL will cause immediate release from the study with documented rationale for exit.

Contacts and Locations

Locations

SiteCityStateCountryPostal Code
1SightMDBabylonNew YorkUnited States11702

Sponsors and Collaborators

  • Alanna Nattis, DO

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Additional Information:

Publications

Responsible Party:
Alanna Nattis, DO, Director of Clinical Research, Ophthalmologist, Sight Medical Doctors PLLC
ClinicalTrials.gov Identifier:
NCT04570579
Other Study ID Numbers:
  • EDOF Lifestyle Enhancement
First Posted:
Sep 30, 2020
Last Update Posted:
Aug 24, 2021
Last Verified:
Aug 1, 2021
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
Yes
Product Manufactured in and Exported from the U.S.:
No
Keywords provided by Alanna Nattis, DO, Director of Clinical Research, Ophthalmologist, Sight Medical Doctors PLLC
Additional relevant MeSH terms:

Study Results

No Results Posted as of Aug 24, 2021